

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/ICD0845AE60EN.html>

Date: July 2018

Pages: 68

Price: US\$ 3,500.00 (Single User License)

ID: ICD0845AE60EN

Abstracts

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'Integrin Beta 3 - Pipeline Review, H2 2018'; Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) pipeline Target constitutes close to 22 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Integrin beta-3 (?3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Activation of integrin alpha-IIb/beta-3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.

The report 'Integrin Beta 3 - Pipeline Review, H2 2018' outlays comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein

IIIa or CD61 or ITGB3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, IND/CTA Filed and Preclinical stages are 3, 1 and 11 respectively. Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Report covers products from therapy areas Oncology, Ophthalmology, Cardiovascular, Metabolic Disorders, Dermatology, Gastrointestinal and Infectious Disease which include indications Wet (Neovascular/Exudative) Macular Degeneration, Breast Cancer, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Melanoma, Wounds, Arterial Thrombosis, Cardiovascular Disease, Diabetic Macular Edema, Diabetic Retinopathy, Ischemic Cerebral Stroke, Ischemic Stroke, Lung Cancer, Malabsorption Syndrome, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Pancreatic Cancer, Retinal Vein Occlusion, Sepsis and Venous Leg Ulcers (Crural ulcer).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)

The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Overview

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Companies
Involved in Therapeutics Development

Celltrion Inc

Factor Therapeutics Ltd

Merck & Co Inc

SciFluor Life Sciences LLC

Vascular Pharmaceuticals Inc

VDDI Pharmaceuticals

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Drug Profiles

A-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AC-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-16Y - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cilengitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonise ITGA5 and ITGB3 for Ischemic Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-0429 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSP-68 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCU-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proagio - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
RSF-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RUC-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-0166 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetraiodothyroacetic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VF-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VF-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VF-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPI-2690B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
xemilofiban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Dormant Products

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Discontinued Products

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Product Development Milestones

Featured News & Press Releases

Jun 26, 2018: VF00102 CLINICAL TRIAL UPDATE: Screening Closed to New Patients as Recruitment Nears Completion

Jun 14, 2018: Factor Therapeutics: VF001002 Clinical Trial Update

May 14, 2018: Factor Therapeutics announces its VF00102 Clinical Trial Recruitment Enters Final Phase

Apr 10, 2018: Factor Therapeutics Provides Update on VF00102 Clinical Trial

Dec 18, 2017: SciFluor announces positive top-line results of phase 1/2 study of SF0166 eye drops to treat wet age-related macular degeneration

Dec 12, 2017: SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases

Nov 29, 2017: Factor Therapeutics Announces 50% Recruitment Reached in VF00102 Clinical Trial

Nov 02, 2017: VF001002 Clinical Trial Update: Strong performance in October driven by new sites

Sep 28, 2017: SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients

May 22, 2017: Factor Therapeutics Appoints Dr. Rosalind Wilson as CEO

May 08, 2017: Ocugen Expands Global Patent Portfolio for OCU200

Apr 07, 2017: Factor Therapeutics: Phase II Clinical Trial Progress Update

Dec 20, 2016: Factor Therapeutics - First Patient In and Clinical Update

Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001)

Oct 17, 2016: SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Celltrion Inc, H2 2018
Pipeline by Factor Therapeutics Ltd, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by SciFluor Life Sciences LLC, H2 2018
Pipeline by Vascular Pharmaceuticals Inc, H2 2018
Pipeline by VDDI Pharmaceuticals, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Celltrion Inc

Factor Therapeutics Ltd

Merck & Co Inc

SciFluor Life Sciences LLC

Vascular Pharmaceuticals Inc

VDDI Pharmaceuticals

I would like to order

Product name: Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/ICD0845AE60EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ICD0845AE60EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

